# Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer After Radio-chemotherapy

> **NCT03255252** · PHASE2 · TERMINATED · sponsor: **Institut du Cancer de Montpellier - Val d'Aurelle** · enrollment: 29 (actual)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** Cisplatin injection
- **COMBINATION_PRODUCT:** radiotherapy

## Key facts

- **NCT ID:** NCT03255252
- **Lead sponsor:** Institut du Cancer de Montpellier - Val d'Aurelle
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-15
- **Primary completion:** 2022-06-16
- **Final completion:** 2023-11-23
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** insufficient recruitment
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03255252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03255252, "Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer After Radio-chemotherapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03255252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*